Literature DB >> 30986706

Melanoma during fingolimod treatment for multiple sclerosis.

C Velter1, M Thomas2, A Cavalcanti3, M Bastien4, F Chochon5, C Lubetzki5, E Routier2, C Robert6.   

Abstract

Entities:  

Keywords:  Adverse effect; FTY720; Fingolimod; Melanoma; Multiple sclerosis; Side effect

Year:  2019        PMID： 30986706     DOI： 10.1016/j.ejca.2019.03.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

Review 1.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

2.  Dynamic Balance of Microglia and Astrocytes Involved in the Remyelinating Effect of Ginkgolide B.

Authors:  Jun-Jun Yin; Yan He; Jun An; Qiang Miao; Ruo-Xuan Sui; Qing Wang; Jie-Zhong Yu; Bao-Guo Xiao; Cun-Gen Ma
Journal:  Front Cell Neurosci       Date:  2020-01-08       Impact factor: 5.505

3.  Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Authors:  Omar Hasan Ali; Fiamma Berner; Christoph Jakob Ackermann; Sandra Stephanie Ring; Alexandre Moulin; Joachim Müller; Eva Markert; Oltin Tiberiu Pop; Stefanie Müller; Stefan Diem; Thomas Hundsberger; Lukas Flatz
Journal:  Cancer Immunol Immunother       Date:  2020-08-17       Impact factor: 6.968
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.